Biogen Looks to Extend its MS Leadership Through Licensing

By Jasmine Kalsi

Pharma Deals Review: Vol 2017 Issue 12 (Table of Contents)

Published: 19 Dec-2017

DOI: 10.3833/pdr.v2017.i12.2290     ISSN: 1756-7874

Section: Licensing



In order to mitigate the threat to its multiple sclerosis (MS) franchise, Biogen has in-licensed Alkermes’ ALKS-8700; a drug which was developed to match the efficacy and have an improved safety profile compared with Biogen’s Tecfidera® (dimethyl fumarate)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details